Ledger.Open graph →

SEC Form D · Amendment · filed March 25, 2016

Nightingale Pharmaceuticals, Inc

Offering

$2.0M

Sold

$1.7M

Exemption

Rule 506(b)

Industry

Pharmaceuticals

Location

NATIONAL CITY, CA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (14)

David Church · NATIONAL CITY, CAExec · Director Lorens Attisha · NATIONAL CITY, CAExec · Director Talal (Brian) Sheena · NATIONAL CITY, CAExec · Director Melwyn Abreo · NATIONAL CITY, CAExec · Director Carol Mcbride · NATIONAL CITY, CAExec · Director Philip A. Hyun · New York, NYExec · Director Steve Case · WASHINGTON, Washington, D.C.Exec · Director Barry W. Farkas · Brooklyn, NYExec · Director Lance L. Odden · New York, NYExec · Director Pier L. Friend · New York, NYExec · Director Andrew L. Vogelstein · New York, NYExec · Director Ted Leonsis · WASHINGTON, Washington, D.C.Exec · Director Sami Mnaymneh · Miami, FLExec · Director Jonathan Roney · Camana Bay, Cayman IslandsExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗